Men's Health Women's Health Senior's Health Antioxidants Sports Nutrition Diet & Weight Loss Vitamins & Minerals Herbs Specialty Supplements Targeted Supplements Spa Products Anti-Aging Basics Body Systems Body Structure Book Store Pet Health My Recommendation My Favorite Articles Our Most Popular Specials Bargain Basement Brands Free Samples

MSM

Health News Archive 26 - Arthritis
<<back to structure/function index

• Cetylated Fatty Acids Improve Knee Function in Patients with Osteoarthritis
• Verification of the Anti-Arthritis Properties of Cetyl Myristoleate Administered Orally and by Injection

Cetylated Fatty Acids Improve Knee Function in Patients with Osteoarthritis

OBJECTIVE: To determine the benefit of cetylated fatty acids (CFA) on knee range of motion and function in patients with osteoarthritis (OA).

METHODS: Sixty-four patients with chronic knee OA were evaluated at baseline and at 30 and 68 days after consuming either placebo (vegetable oil; n = 31) or CFA (Celadrin; n = 33). Evaluations included physician assessment, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI).

RESULTS: After 68 days, patients treated with CFA exhibited significant (p < 0.001) increase in knee flexion (10.1 degrees) compared to patients given placebo (1.1 degrees). Neither group reported improvement in knee extension. Patient responses to the LAI indicated a significant (p < 0.001) shift towards functional improvement for the CFA group (-5.4 points) after 68 days compared to a modest improvement in the placebo group (-2.1 points).

CONCLUSION: Compared to placebo, CFA provides an improvement in knee range of motion and overall function in patients with OA of the knee. CFA may be an alternative to the use of nonsteroidal antiinflammatory drugs for the treatment of OA.

SOURCE: J Rheumatol. 2002 Aug;29(8):1708-12.  Authors: Hesslink R Jr, Armstrong D 3rd, Nagendran MV, Sreevatsan S, Barathur R.

back to top

Verification of the Anti-Arthritis Properties of Cetyl Myristoleate Administered Orally and by Injection

Hunter KW, Gault RA, Stehouwer JS, Tam-Chang SW.

Department of Microbiology, University of Nevada School of Medicine, 89557, Reno, NV, USA

OBJECTIVE & METHODS: Cetyl myristoleate (CMO) was reported by Diehl and May [J Pharm Sci 83 (1994) 296] to block inflammation and prevent adjuvant-induced arthritis in rats. To verify this earlier work, we have synthesized pure CMO and tested its anti-arthritic properties in a collagen-induced arthritis model in DBA/1LacJ mice.

RESULTS: Multiple intraperitoneal injections of CMO in 450 and 900mgkg(-1) doses resulted in a significantly lower incidence of disease and caused a modest but significant diminution in clinical signs in those mice that developed arthritis. CMO administered in daily oral doses of 20mgkg(-1) also reduced the incidence of arthritis and caused a small reduction in the clinical signs in mice that developed arthritis.

CONCLUSION: Although the protective effect of CMO in collagen-induced arthritis observed in the present study was less dramatic than that reported earlier, our results confirm the anti-arthritic properties of pure CMO.

Source: Pharmacol Res. 2003 Jan;47(1):43-7.

back to top